# Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

> **NCT06406400** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 15 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** AZD4041
- **DRUG:** Itraconazole
- **DRUG:** Buprenorphine
- **DRUG:** Buprenorphine / Naloxone
- **DRUG:** Hydromorphone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06406400
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-13
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study terminated due to discontinuation of the AZD4041 clinical development program for OUD.
- **Last updated:** 2025-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406400, "Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06406400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*